Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 4 10 versus TRIAVIL 4 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 4 10 versus TRIAVIL 4 50.
TRIAVIL 4-10 vs TRIAVIL 4-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of serotonin and norepinephrine. Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
One tablet (4 mg perphenazine / 50 mg amitriptyline) orally three times daily to four times daily. Maximum: 8 tablets per day.
None Documented
None Documented
Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine.
Amitriptyline: 15-40 hours (mean 20-30 hours); perphenazine: 9-12 hours; clinical context: steady-state achieved within 5-7 days, dosing adjustments needed in hepatic impairment.
Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination).
Renal: 50-60% as metabolites (amitriptyline and perphenazine), <5% unchanged; fecal: 20-30% (primarily perphenazine metabolites); biliary: minor route for perphenazine.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination